ABSTRACT
Yet, even in the most expert hands, there remains a subgroup of patients who cannot be optimally primarily cytoreduced and many of these patients may be better served by NAC and interval cytoreduction if there is clinical evidence of the tumor’s response to chemotherapy. The challenge lies in predicting in whom optimal cytoreduction is likely feasible or not (see below, section on neoadjuvant chemotherapy followed by delayed primary cytoreduction and selection criteria).
